Cover Image
Market Research Report
Product code 
1092259

Regulatory Affairs Outsourcing Market - Global Outlook and Forecast 2022-2027

Published: | Arizton Advisory & Intelligence | 345 Pages | Delivery time: 1-2 business days

Price

Back to Top
Regulatory Affairs Outsourcing Market - Global Outlook and Forecast 2022-2027
Published: June 20, 2022
Arizton Advisory & Intelligence
Content info: 345 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

The Global Regulatory Affairs Outsourcing Market is expected to grow at a CAGR of 12.73%.

The following factors will drive the global regulatory affairs outsourcing market growth during the forecast period:

  • Increasing Use of Digital Platforms/Solutions in Regulatory Affairs
  • Changing Regulatory Landscape
  • Rising Demand For Fast Drug & Medical Device Approvals
  • Impact of Strict Government Regulations

REGULATORY AFFAIRS OUTSOURCING MARKET SCENARIO

RA serves as the interface between the regulatory authorities and companies, acts as the channel of communication with the regulatory authorities as to the approval process proceeds, and ensures that the approval will be executed effectively. RA outsourcing companies help biopharma and MedTech companies handle regulatory approval workflows flexibly, productively, and efficiently. Regulatory affairs service providers offer comprehensive services to companies, from strategic regulatory advice to regulatory maintenance and lifecycle support. It is the responsibility of RA outsourcing companies to keep abreast of current legislation, guidelines, and other regulatory intelligence.

  • Across the world, there have been growing cases of chronic illness or infectious diseases, patent expirations of prescription biologics, developments of biosimilars/orphan drugs and cell and gene therapy products, brand extensions, easy accessibility of OTC drugs across various platforms, economic and social factors, increasing healthcare expenditures, and advancements in regulatory affairs outsourcing, which are increasing the demand for regulatory affairs outsourcing services.
  • The healthcare industry is witnessing new compounds originating outside the companies ultimately responsible for marketing them. For instance, around one-third of approved drugs commercialized by big pharma/biotech companies were sourced from outside a decade ago. Approximately 50% to 70% of large companies' pipeline molecules are currently sourced outside.
  • In recent years, both pharma and medical device industries have witnessed many M&As, with oncology, orthopedic, and cardiovascular diseases being a particular area of interest. For instance, the pharma industry saw around 2,880 deals worth more than $1 trillion between 2014 and the first half of 2019 in gene therapy, immuno-oncology, microbiome, and orphan drugs.
  • The healthcare regulatory affairs outsourcing market is highly competitive and competes with traditional CROs and in-house regulatory affairs departments in pharma/biotech and medical device companies.

Increasing Development of Biosimilars, Orphan Drugs, and Personalized Medicines

  • Over the last two decades, a transformation has occurred in treating many chronic and highly complex diseases like autoimmune disorders, cancer, and diabetes, introducing biopharmaceuticals.
  • Over the next five years, it is expected that the number of biosimilars and their market authorization will increase significantly as top-selling biologics such as Herceptin (Trastuzumab; Roche/Genentech), Enbrel (Etanercept; Amgen), Humalog (Insulin Lispro;), MabThera (Ritziximab; Roche, Basel), and Aranep (Darbepoetin Alpha; Amgen) go off patent.
  • Pfizer has agreed with Biocon (India) to produce biosimilar insulin. Eli Lilly and AstraZeneca have announced plans to produce biosimilars, and Boehringer Ingelheim has established a specialized business to develop and sell biosimilars.
  • Another challenge for pharmaceutical companies and other life sciences companies is anticipating the regulation of personalized medicine such as gene therapy and cell therapy. As R&D related to human cell and gene therapy grows rapidly, all stakeholders need to be aware of regulatory changes quickly.

The emergence of Virtual Trials and Virtual Communication

  • Many regulatory authorities around the globe issued guidance documents containing information on how trials could continue during the pandemic, which includes the US Food and Drug Administration (FDA), European Medicines Agency (EMA), Medicines and Healthcare Products Regulatory Agency (MHRA), and Singapore's Health Science Authority.
  • The COVID-19 pandemic has energized the ascent of clinical trials without clinical sites and made way for proceeding with these inventive models after the general well-being emergency has blurred.
  • A constellation of emerging technology and services has permitted the relocation of clinical-trial activities closer to patients. Without in-person visits, investigators can maintain relationships with study participants using electronic consent, telehealthcare, remote patient monitoring, and electronic clinical outcome assessments (eCOAs).
  • Before the pandemic, an Industry Standard Research survey in December 2019 found that 38% of pharma and contract research organizations (CROs) expected virtual trials to be a major part of their portfolios, and 48% expected to run a trial with most activities taking place in participants' homes.
  • Sponsors and service providers attempting to execute decentralized trials must manage technological and approach uncertainties while balancing the demands of each stakeholder group and providing a good, distinctive experience.

Changing Regulatory Landscape

  • In recent years, life sciences companies have faced increasing pressure, including regulatory requirements, technological advances, and pricing pressure. COVID-19 has only provided more reasons for modernizing compliance and improving values and partnerships within the organization and with external stakeholders.
  • A recent global survey of pharmaceutical company CEOs reveals that regulations are being scrutinized for many aspects of business, including sales and marketing practices, government reporting of drug prices, privacy controls, and clinical practice.
  • Changes in the regulation viewed it as one of the top three disruptive business trends facing pharmaceutical and life sciences companies. Large pharmaceutical companies recognize these changes as the greatest threat to their potential future growth.
  • Contract research organizations (CROs) are well experienced and have updated on all changes in regulatory affairs in the pharmaceutical or the medical device industry. Thus, the pharmaceutical and medical devices companies are increasingly outsourcing the regulatory affairs activities to CROs.

GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET SEGMENTS

The small molecules drugs market size will cross USD 3 billion in 2022. For many decades, small molecule drug compounds have been the mainstay of the pharmaceutical industry. Small molecule drugs continue to play an essential role in developing new therapies globally. The demand for small molecule drugs remains high, with around 97% of the commercial drugs available in the market classified as small molecules.

The biologics segment will likely witness a faster growth rate due to a surge in demand for biopharmaceuticals like mAbs, vaccines, cell & gene therapies, recombinant proteins, etc.

Major Biologics & Their Revenue in 2019 & 2020

  • In 2020, one of the key companies, AbbVie, has sold around USD 19.8 billion worth of HUMIRA drugs compared to USD 19.1 billion in 2019, which shows an increment of almost 3.5% in sales.
  • Johnson & Johnson sold approximately USD 7.7 billion worth of STELARA drugs in 2020, compared to USD 6.3 billion in 2019, representing a more than 21% increase in sales.
  • In 2020, Merck & Co. sold around USD 14 billion worth of KEYTRUDA drugs, up from USD 11 billion in 2019. This is a more than 29% increase in sales.

The small & mid-sized companies reported a major share of around 63.73% of the global regulatory affairs outsourcing market. Small and Medium-sized companies are leading because small and Medium-sized pharmaceutical companies outsource about 90% and 75% of their regulatory requirements. These companies often face resource and technology shortages and partner with suppliers on a project basis.

The pharma & biotech companies market reported a major share of around 65.19%. Pharmaceutical and biotechnology companies have partnered with contract research organizations (CROs) for outsourcing needs, including regulatory services. Most companies choose CROs for outsourcing regulatory services. They believe that regulatory outsourcing companies have the conceptual and technical expertise to achieve efficient results.

The pre-authorization market reported a major share of around 55.48% of the global regulatory affairs outsourcing market. US and EU health authorities require most regulatory applications to be received in ICH harmonized CTD format in the current regulatory era. A thorough submission approach and standardized CTD document templates enable effective regulatory submissions and subsequent lifecycle management with shorter and cost-effective parameters.

The North American region dominates the regulatory affairs outsourcing market with around 33% of the market share. The US is the major revenue contributor to the North American regulatory affairs outsourcing market and accounted for around 91% in 2021. The region's growth is primarily attributed to the increasing number of chronic diseases, development of biologics & biosimilars, increasing healthcare expenditures, and increasing innovation & advancements in regulatory affairs outsourcing.

Segmentation by Product

  • Small Molecule Drugs
  • Biologics
  • Medical Devices
  • Others

Segmentation by Company Size

  • Small & Mid-Sized Companies
  • Large-sized Companies

Segmentation by End-User

  • Pharma & Biotech Companies
  • Medical Device Companies
  • Other Companies

Segmentation by Service Type

  • Pre-Authorization
  • Marketing Authorization
  • Post-Authorization

Segmentation by Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
  • APAC
    • China
    • Japan
    • Australia
    • South Korea
    • India
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • South Africa

Key Vendors

  • Genpact
  • Labcorp Drug Development
  • Freyr
  • ICON
  • IQVIA
  • Medpace
  • Parexel International
  • PPD

Other Prominent Vendors

  • Accenture
  • BlueReg
  • Intertek Group
  • Lachman Consultants
  • NDA Group
  • ProPharma Group
  • PharmaLex
  • Pharmexon
  • Promedica International
  • CRITERIUM
  • Dicentra
  • Nuventra Pharma Sciences
  • PharmaLeaf
  • MAVEN REGULATORY SOLUTIONS
  • Global Regulatory Partners
  • Sofpromed
  • Charles River Laboratories
  • Cambridge Regulatory Services
  • APC Group
  • Real Regulatory
  • Voisin Consulting Life Sciences (VCLS)
  • Regulatory Pharma Net
  • Biomapas
  • REGENOLD

KEY QUESTIONS ANSWERED

  • 1. What will be the size of the Regulatory Affairs Outsourcing Market by 2028?
  • 2. What are the factors driving the market growth?
  • 3. Who are the key vendors in the regulatory affairs outsourcing industry?
  • 4. Which region holds the highest growth rate in the regulatory affairs outsourcing industry?
Product Code: Sample_Regulatory Affairs Outsourcing Market - Global Outlook & Forecast 2022-2027_Arizton.pdf

TABLE OF CONTENTS

1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 SCOPE & COVERAGE

  • 4.1 MARKET DEFINITION
    • 4.1.1 INCLUSIONS
    • 4.1.2 EXCLUSIONS
    • 4.1.3 MARKET ESTIMATION CAVEATS
  • 4.2 BASE YEAR
  • 4.3 SCOPE OF THE STUDY
  • 4.4 MARKET SEGMENTATION
    • 4.4.1 MARKET SEGMENTATION BY PRODUCT
    • 4.4.2 MARKET SEGMENTATION BY COMPANY SIZE
    • 4.4.3 MARKET SEGMENTATION BY END-USER
    • 4.4.4 MARKET SEGMENTATION BY SERVICE TYPE
    • 4.4.5 MARKET SEGMENTATION BY GEOGRAPHY

5 REPORT ASSUMPTIONS & CAVEATS

  • 5.1 KEY CAVEATS
  • 5.2 CURRENCY CONVERSION
  • 5.3 MARKET DERIVATION

6 MARKET AT A GLANCE

7 INTRODUCTION

  • 7.1 OVERVIEW
    • 7.1.1 THE NEED FOR REGULATORY AFFAIRS
    • 7.1.2 ROLE OF REGULATORY BODIES/AGENCIES
    • 7.1.3 REASONS TO OUTSOURCE REGULATORY AFFAIRS

8 MARKET OPPORTUNITIES & TRENDS

  • 8.1 INCREASING DEVELOPMENT OF BIOSIMILARS, ORPHAN DRUGS, AND PERSONALIZED MEDICINES
  • 8.2 IMPACT OF COVID-19
  • 8.3 ADVANCEMENTS IN REGULATORY AFFAIRS SERVICES
  • 8.4 EMERGENCE OF VIRTUAL TRIALS & VIRTUAL COMMUNICATION

9 MARKET GROWTH ENABLERS

  • 9.1 INCREASING USE OF DIGITAL PLATFORMS/SOLUTIONS IN REGULATORY AFFAIRS
  • 9.2 CHANGING REGULATORY LANDSCAPE
  • 9.3 RISING DEMAND FOR FAST DRUG & MEDICAL DEVICE APPROVALS
  • 9.4 STRICT GOVERNMENT REGULATIONS

10 MARKET RESTRAINTS

  • 10.1 CONCERNS OVER DATA BREACHES & PRIVACY ISSUES AMONG END-USERS
  • 10.2 DEARTH OF SKILLED PROFESSIONALS IN REGULATORY AFFAIRS OUTSOURCING
  • 10.3 LACK OF STANDARDIZATION & MONITORING ISSUES IN REGULATORY AFFAIRS

11 MARKET LANDSCAPE

  • 11.1 MARKET OVERVIEW
  • 11.2 MARKET SIZE & FORECAST
    • 11.2.1 INSIGHTS BY GEOGRAPHY
    • 11.2.2 INSIGHTS BY PRODUCT
    • 11.2.3 INSIGHTS BY COMPANY SIZE
    • 11.2.4 INSIGHTS BY END-USER
    • 11.2.5 INSIGHTS BY SERVICE TYPE
  • 11.3 FIVE FORCES ANALYSIS
    • 11.3.1 THREAT OF NEW ENTRANTS
    • 11.3.2 BARGAINING POWER OF SUPPLIERS
    • 11.3.3 BARGAINING POWER OF BUYERS
    • 11.3.4 THREAT OF SUBSTITUTES
    • 11.3.5 COMPETITIVE RIVALRY

12 PRODUCT

  • 12.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 12.2 MARKET OVERVIEW
  • 12.3 SMALL MOLECULE DRUGS
    • 12.3.1 MARKET OVERVIEW
    • 12.3.2 MARKET SIZE & FORECAST
    • 12.3.3 SMALL MOLECULE DRUGS: GEOGRAPHY SEGMENTATION
  • 12.4 BIOLOGICS
    • 12.4.1 MARKET OVERVIEW
    • 12.4.2 MARKET SIZE & FORECAST
    • 12.4.3 BIOLOGICS: GEOGRAPHY SEGMENTATION
  • 12.5 MEDICAL DEVICES
    • 12.5.1 MARKET OVERVIEW
    • 12.5.2 MARKET SIZE & FORECAST
    • 12.5.3 MEDICAL DEVICES: GEOGRAPHY SEGMENTATION
  • 12.6 OTHERS
    • 12.6.1 MARKET OVERVIEW
    • 12.6.2 MARKET SIZE & FORECAST
    • 12.6.3 OTHERS: GEOGRAPHY SEGMENTATION

13 COMPANY SIZE

  • 13.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 13.2 MARKET OVERVIEW
  • 13.3 SMALL & MID-SIZED COMPANIES
    • 13.3.1 MARKET OVERVIEW
    • 13.3.2 MARKET SIZE & FORECAST
    • 13.3.3 SMALL & MID-SIZED COMPANIES: GEOGRAPHY SEGMENTATION
  • 13.4 LARGE-SIZED COMPANIES
    • 13.4.1 MARKET OVERVIEW
    • 13.4.2 MARKET SIZE & FORECAST
    • 13.4.3 LARGE-SIZED COMPANIES: GEOGRAPHY SEGMENTATION

14 END-USER

  • 14.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 14.2 MARKET OVERVIEW
  • 14.3 PHARMA & BIOTECH COMPANIES
    • 14.3.1 MARKET OVERVIEW
    • 14.3.2 MARKET SIZE & FORECAST
    • 14.3.3 PHARMA & BIOTECH COMPANIES: GEOGRAPHY SEGMENTATION
  • 14.4 MEDICAL DEVICE COMPANIES
    • 14.4.1 MARKET OVERVIEW
    • 14.4.2 MARKET SIZE & FORECAST
    • 14.4.3 MEDICAL DEVICE COMPANIES: GEOGRAPHY SEGMENTATION
  • 14.5 OTHER COMPANIES
    • 14.5.1 MARKET OVERVIEW
    • 14.5.2 MARKET SIZE & FORECAST
    • 14.5.3 OTHER COMPANIES: GEOGRAPHY SEGMENTATION

15 SERVICE TYPE

  • 15.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 15.2 MARKET OVERVIEW
  • 15.3 PRE-AUTHORIZATION
    • 15.3.1 MARKET OVERVIEW
    • 15.3.2 MARKET SIZE & FORECAST
    • 15.3.3 PRE-AUTHORIZATION: GEOGRAPHY SEGMENTATION
  • 15.4 MARKETING AUTHORIZATION
    • 15.4.1 MARKET OVERVIEW
    • 15.4.2 MARKET SIZE & FORECAST
    • 15.4.3 MARKETING AUTHORIZATION: GEOGRAPHY SEGMENTATION
  • 15.5 POST-AUTHORIZATION
    • 15.5.1 MARKET OVERVIEW
    • 15.5.2 MARKET SIZE & FORECAST
    • 15.5.3 POST-AUTHORIZATION: GEOGRAPHY SEGMENTATION

16 GEOGRAPHY

  • 16.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 16.2 GEOGRAPHIC OVERVIEW

17 NORTH AMERICA

  • 17.1 MARKET OVERVIEW
  • 17.2 MARKET SIZE & FORECAST
    • 17.2.1 NORTH AMERICA: PRODUCT SEGMENTATION
    • 17.2.2 NORTH AMERICA: COMPANY SIZE SEGMENTATION
    • 17.2.3 NORTH AMERICA: END-USER SEGMENTATION
    • 17.2.4 NORTH AMERICA: SERVICE TYPE SEGMENTATION
  • 17.3 KEY COUNTRIES
    • 17.3.1 US: MARKET SIZE & FORECAST
    • 17.3.2 CANADA: MARKET SIZE & FORECAST

18 EUROPE

  • 18.1 MARKET OVERVIEW
  • 18.2 MARKET SIZE & FORECAST
    • 18.2.1 EUROPE: PRODUCT SEGMENTATION
    • 18.2.2 EUROPE: COMPANY SIZE SEGMENTATION
    • 18.2.3 EUROPE: END-USER SEGMENTATION
    • 18.2.4 EUROPE: SERVICE TYPE SEGMENTATION
  • 18.3 KEY COUNTRIES
    • 18.3.1 GERMANY: MARKET SIZE & FORECAST
    • 18.3.2 FRANCE: MARKET SIZE & FORECAST
    • 18.3.3 UK: MARKET SIZE & FORECAST
    • 18.3.4 ITALY: MARKET SIZE & FORECAST
    • 18.3.5 SPAIN: MARKET SIZE & FORECAST

19 APAC

  • 19.1 MARKET OVERVIEW
  • 19.2 MARKET SIZE & FORECAST
    • 19.2.1 APAC: PRODUCT SEGMENTATION
    • 19.2.2 APAC: COMPANY SIZE SEGMENTATION
    • 19.2.3 APAC: END-USER SEGMENTATION
    • 19.2.4 APAC: SERVICE TYPE SEGMENTATION
  • 19.3 KEY COUNTRIES
    • 19.3.1 JAPAN: MARKET SIZE & FORECAST
    • 19.3.2 CHINA: MARKET SIZE & FORECAST
    • 19.3.3 SOUTH KOREA: MARKET SIZE & FORECAST
    • 19.3.4 INDIA: MARKET SIZE & FORECAST
    • 19.3.5 AUSTRALIA: MARKET SIZE & FORECAST

20 LATIN AMERICA

  • 20.1 MARKET OVERVIEW
  • 20.2 MARKET SIZE & FORECAST
    • 20.2.1 LATIN AMERICA: PRODUCT SEGMENTATION
    • 20.2.2 LATIN AMERICA: COMPANY SIZE SEGMENTATION
    • 20.2.3 LATIN AMERICA: END-USER SEGMENTATION
    • 20.2.4 LATIN AMERICA: SERVICE TYPE SEGMENTATION
  • 20.3 KEY COUNTRIES
    • 20.3.1 BRAZIL: MARKET SIZE & FORECAST
    • 20.3.2 MEXICO: MARKET SIZE & FORECAST
    • 20.3.3 ARGENTINA: MARKET SIZE & FORECAST

21 MIDDLE EAST & AFRICA

  • 21.1 MARKET OVERVIEW
  • 21.2 MARKET SIZE & FORECAST
    • 21.2.1 MIDDLE EAST & AFRICA: PRODUCT SEGMENTATION
    • 21.2.3 MIDDLE EAST & AFRICA: COMPANY SIZE SEGMENTATION
    • 21.2.4 MIDDLE EAST & AFRICA: END-USER SEGMENTATION
    • 21.2.6 MIDDLE EAST & AFRICA: SERVICE TYPE SEGMENTATION
  • 21.3 KEY COUNTRIES
    • 21.3.1 TURKEY: MARKET SIZE & FORECAST
    • 21.3.2 SAUDI ARABIA: MARKET SIZE & FORECAST
    • 21.3.3 SOUTH AFRICA: MARKET SIZE & FORECAST
    • 21.3.4 UAE: MARKET SIZE & FORECAST

22 COMPETITIVE LANDSCAPE

  • 22.1 COMPETITION OVERVIEW
  • 22.2 MARKET SHARE ANALYSIS
    • 22.2.1 FREYR
    • 22.2.2 GENPACT
    • 22.2.3 ICON
    • 22.2.4 IQVIA
    • 22.2.5 LABCORP DRUG DEVELOPMENT
    • 22.2.6 MEDPACE
    • 22.2.7 PPD
    • 22.2.8 PAREXEL

23 KEY COMPANY PROFILES

  • 23.1 GENPACT
    • 23.1.1 BUSINESS OVERVIEW
    • 23.1.2 SERVICE OFFERINGS
    • 23.1.3 KEY STRATEGIES
    • 23.1.4 KEY STRENGTHS
    • 23.1.5 KEY OPPORTUNITIES
  • 23.2 LABCORP DRUG DEVELOPMENT
    • 23.2.1 BUSINESS OVERVIEW
    • 23.2.2 SERVICE OFFERINGS
    • 23.2.3 KEY STRATEGIES
    • 23.2.4 KEY STRENGTHS
    • 23.2.5 KEY OPPORTUNITIES
  • 23.3 FREYR
    • 23.3.1 BUSINESS OVERVIEW
    • 23.3.2 SERVICE OFFERINGS
    • 23.3.3 KEY STRATEGIES
    • 23.3.4 KEY STRENGTHS
    • 23.3.5 KEY OPPORTUNITIES
  • 23.4 ICON
    • 23.4.1 BUSINESS OVERVIEW
    • 23.4.2 SERVICE OFFERINGS
    • 23.4.3 KEY STRATEGIES
    • 23.4.4 KEY STRENGTHS
    • 23.4.5 KEY OPPORTUNITIES
  • 23.5 IQVIA
    • 23.5.1 BUSINESS OVERVIEW
    • 23.5.2 SERVICE OFFERINGS
    • 23.5.3 KEY STRATEGIES
    • 23.5.4 KEY STRENGTHS
    • 23.5.5 KEY OPPORTUNITIES
  • 23.6 MEDPACE
    • 23.6.1 BUSINESS OVERVIEW
    • 23.6.2 SERVICE OFFERINGS
    • 23.6.3 KEY STRATEGIES
    • 23.6.4 KEY STRENGTHS
    • 23.6.5 KEY OPPORTUNITIES
  • 23.7 PAREXEL INTERNATIONAL
    • 23.7.1 BUSINESS OVERVIEW
    • 23.7.2 SERVICE OFFERINGS
    • 23.7.3 KEY STRATEGIES
    • 23.7.4 KEY STRENGTHS
    • 23.7.5 KEY OPPORTUNITIES
  • 23.8 PPD
    • 23.8.1 BUSINESS OVERVIEW
    • 23.8.2 SERVICE OFFERINGS
    • 23.8.3 KEY STRATEGIES
    • 23.8.4 KEY STRENGTHS
    • 23.8.5 KEY OPPORTUNITIES

24 OTHER PROMINENT VENDORS

  • 24.1 ACCENTURE
    • 24.1.1 BUSINESS OVERVIEW
    • 24.1.2 SERVICE OFFERINGS
  • 24.2 BLUEREG
    • 24.2.1 BUSINESS OVERVIEW
    • 24.2.2 SERVICE OFFERINGS
  • 24.3 INTERTEK GROUP
    • 24.3.1 BUSINESS OVERVIEW
    • 24.3.2 SERVICE OFFERINGS
  • 24.4 LACHMAN CONSULTANTS
    • 24.4.1 BUSINESS OVERVIEW
    • 24.4.2 SERVICE OFFERINGS
  • 24.5 NDA GROUP
    • 24.5.1 BUSINESS OVERVIEW
    • 24.5.2 SERVICE OFFERINGS
  • 24.6 PROPHARMA GROUP
    • 24.6.1 BUSINESS OVERVIEW
    • 24.6.2 SERVICE OFFERINGS
  • 24.7 PHARMALEX
    • 24.7.1 BUSINESS OVERVIEW
    • 24.7.2 SERVICE OFFERINGS
  • 24.8 PHARMEXON
    • 24.8.1 BUSINESS OVERVIEW
    • 24.8.2 SERVICE OFFERINGS
  • 24.9 PROMEDICA INTERNATIONAL
    • 24.9.1 BUSINESS OVERVIEW
    • 24.9.2 SERVICE OFFERINGS
  • 24.10 CRITERIUM
    • 24.10.1 BUSINESS OVERVIEW
    • 24.10.2 SERVICE OFFERINGS
  • 24.11 DICENTRA
    • 24.11.1 BUSINESS OVERVIEW
    • 24.11.2 SERVICE OFFERINGS
  • 24.12 NUVENTRA PHARMA SCIENCES
    • 24.12.1 BUSINESS OVERVIEW
    • 24.12.2 SERVICE OFFERINGS
  • 24.13 PHARMALEAF
    • 24.13.1 BUSINESS OVERVIEW
    • 24.13.2 SERVICE OFFERINGS
  • 24.14 MAVEN REGULATORY SOLUTIONS
    • 24.14.1 BUSINESS OVERVIEW
    • 24.14.2 SERVICE OFFERINGS
  • 24.15 GLOBAL REGULATORY PARTNERS
    • 24.15.1 BUSINESS OVERVIEW
    • 24.15.2 SERVICE OFFERINGS
  • 24.16 SOFPROMED
    • 24.16.1 BUSINESS OVERVIEW
    • 24.16.2 SERVICE OFFERINGS
  • 24.17 CHARLES RIVER LABORATORIES
    • 24.17.1 BUSINESS OVERVIEW
    • 24.17.2 SERVICE OFFERINGS
  • 24.18 CAMBRIDGE REGULATORY SERVICES
    • 24.18.1 BUSINESS OVERVIEW
    • 24.18.2 SERVICE OFFERINGS
  • 24.19 APC GROUP
    • 24.19.1 BUSINESS OVERVIEW
    • 24.19.2 SERVICE OFFERINGS
  • 24.20 REAL REGULATORY
    • 24.20.1 BUSINESS OVERVIEW
    • 24.20.2 SERVICE OFFERINGS
  • 24.21 VOISIN CONSULTING LIFE SCIENCES (VCLS)
    • 24.21.1 BUSINESS OVERVIEW
    • 24.21.2 SERVICE OFFERINGS
  • 24.22 REGULATORY PHARMA NET
    • 24.22.1 BUSINESS OVERVIEW
    • 24.22.2 SERVICE OFFERINGS
  • 24.23 BIOMAPAS
    • 24.23.1 BUSINESS OVERVIEW
    • 24.23.2 SERVICE OFFERINGS
  • 24.24 REGENOLD
    • 24.24.1 BUSINESS OVERVIEW
    • 24.24.2 SERVICE OFFERINGS

25 REPORT SUMMARY

  • 25.1 KEY TAKEAWAYS
  • 25.2 STRATEGIC RECOMMENDATIONS

26 QUANTITATIVE SUMMARY

  • 26.1 MARKET BY PRODUCT
    • 26.1.1 NORTH AMERICA: PRODUCT SEGMENTATION
    • 26.1.2 EUROPE: PRODUCT SEGMENTATION
    • 26.1.3 APAC: PRODUCT SEGMENTATION
    • 26.1.4 LATIN AMERICA: PRODUCT SEGMENTATION
    • 26.1.5 MIDDLE EAST & AFRICA: PRODUCT SEGMENTATION
  • 26.2 MARKET BY COMPANY SIZE
    • 26.2.1 NORTH AMERICA: COMPANY SIZE SEGMENTATION
    • 26.2.2 EUROPE: COMPANY SIZE SEGMENTATION
    • 26.2.3 APAC: COMPANY SIZE SEGMENTATION
    • 26.2.4 LATIN AMERICA: COMPANY SIZE SEGMENTATION
    • 26.2.5 MIDDLE EAST & AFRICA: COMPANY SIZE SEGMENTATION
  • 26.3 MARKET BY END-USER
    • 26.3.1 NORTH AMERICA: END-USER SEGMENTATION
    • 26.3.2 EUROPE: END-USER SEGMENTATION
    • 26.3.3 APAC: END-USER SEGMENTATION
    • 26.3.4 LATIN AMERICA: END-USER SEGMENTATION
    • 26.3.5 MIDDLE EAST & AFRICA: END-USER SEGMENTATION
  • 26.4 MARKET BY SERVICE TYPE
    • 26.4.1 NORTH AMERICA: SERVICE TYPE SEGMENTATION
    • 26.4.2 EUROPE: SERVICE TYPE SEGMENTATION
    • 26.4.3 APAC: SERVICE TYPE SEGMENTATION
    • 26.4.4 LATIN AMERICA: SERVICE TYPE SEGMENTATION
    • 26.4.5 MIDDLE EAST & AFRICA: SERVICE TYPE SEGMENTATION
  • 26.5 MARKET BY GEOGRAPHY
    • 26.5.1 DRUGS: GEOGRAPHY SEGMENTATION
    • 26.5.2 BIOLOGICS: GEOGRAPHY SEGMENTATION
    • 26.5.3 MEDICAL DEVICES: GEOGRAPHY SEGMENTATION
    • 26.5.4 OTHERS: GEOGRAPHY SEGMENTATION
    • 26.5.5 SMALL & MID-SIZED COMPANIES: GEOGRAPHY SEGMENTATION
    • 26.5.6 LARGE-SIZED COMPANIES: GEOGRAPHY SEGMENTATION
    • 26.5.7 PHARMA & BIOTECH COMPANIES: GEOGRAPHY SEGMENTATION
    • 26.5.8 MEDICAL DEVICE COMPANIES: GEOGRAPHY SEGMENTATION
    • 26.5.9 OTHER COMPANIES: GEOGRAPHY SEGMENTATION
    • 26.5.10 PRE-AUTHORIZATION: GEOGRAPHY SEGMENTATION
    • 26.5.11 MARKETING AUTHORIZATION: GEOGRAPHY SEGMENTATION
    • 26.5.12 POST-AUTHORIZATION: GEOGRAPHY SEGMENTATION

27 APPENDIX

  • 27.1 ABBREVIATIONS

LIST OF EXHIBITS

  • EXHIBIT 1 SEGMENTATION OF GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET
  • EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2021
  • EXHIBIT 3 ROLES OR INTERACTIONS OF RA
  • EXHIBIT 4 IMPACT OF INCREASING DEVELOPMENT OF BIOSIMILARS, ORPHAN DRUGS, AND PERSONALIZED MEDICINES
  • EXHIBIT 5 IMPACT OF COVID-19
  • EXHIBIT 6 LEVERAGING CLOUD TECHNOLOGY FOR REGULATORY AFFAIRS OUTSOURCING
  • EXHIBIT 7 OUTSOURCING IN REGULATORY AFFAIRS
  • EXHIBIT 8 IMPACT OF ADVANCEMENTS IN REGULATORY AFFAIRS SERVICES
  • EXHIBIT 9 IMPACT OF EMERGENCE OF VIRTUAL TRIALS & VIRTUAL COMMUNICATION
  • EXHIBIT 10 IMPACT OF INCREASING USE OF DIGITAL PLATFORMS /SOLUTIONS IN REGULATORY AFFAIRS
  • EXHIBIT 11 IMPACT OF CHANGING REGULATORY LANDSCAPE
  • EXHIBIT 12 IMPACT OF RISING DEMAND FOR FAST DRUG & MEDICAL DEVICE APPROVALS
  • EXHIBIT 13 IMPACT OF STRICT GOVERNMENT REGULATIONS
  • EXHIBIT 14 IMPACT OF CONCERNS OVER DATA BREACHES & PRIVACY ISSUES AMONG END-USERS
  • EXHIBIT 15 IMPACT OF DEARTH OF SKILLED PROFESSIONALS IN REGULATORY AFFAIRS OUTSOURCING
  • EXHIBIT 16 IMPACT OF LACK OF STANDARDIZATION & MONITORING ISSUES IN REGULATORY AFFAIRS
  • EXHIBIT 17 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 18 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY GEOGRAPHY
  • EXHIBIT 19 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY PRODUCT
  • EXHIBIT 20 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY COMPANY SIZE
  • EXHIBIT 21 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY END-USER
  • EXHIBIT 22 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY SERVICE TYPE
  • EXHIBIT 23 FIVE FORCES ANALYSIS 2021
  • EXHIBIT 24 INCREMENTAL GROWTH BY PRODUCT 2021 & 2027
  • EXHIBIT 25 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY PRODUCT
  • EXHIBIT 26 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY PRODUCT: INCREMENTAL GROWTH
  • EXHIBIT 27 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY PRODUCT: ABSOLUTE GROWTH
  • EXHIBIT 28 FOOD SAFETY AND STANDARDS AUTHORITY OF INDIA (FSSAI) REGULATIONS FOR THE FOLLOWING CATEGORIES OF FUNCTIONAL FOODS
  • EXHIBIT 29 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY SMALL MOLECULE DRUGS: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 30 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY SMALL MOLECULE DRUGS 2021-2027 ($ MILLION)
  • EXHIBIT 31 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 32 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY BIOLOGICS: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 33 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY BIOLOGICS 2021-2027 ($ MILLION)
  • EXHIBIT 34 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 35 USFDA MEDICAL DEVICE CLASSIFICATION
  • EXHIBIT 36 GLOBAL REGULATORY AFFAIRS OUTSOURCING MEDICAL DEVICE MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 37 GLOBAL REGULATORY AFFAIRS OUTSOURCING MEDICAL DEVICE MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 38 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 39 GLOBAL REGULATORY AFFAIRS OUTSOURCING OTHER PRODUCTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 40 GLOBAL REGULATORY AFFAIRS OUTSOURCING OTHER PRODUCTS MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 41 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 42 INCREMENTAL GROWTH BY COMPANY SIZE 2021 & 2027
  • EXHIBIT 43 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY COMPANY SIZE
  • EXHIBIT 44 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY COMPANY SIZE: INCREMENTAL GROWTH
  • EXHIBIT 45 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY COMPANY SIZE: ABSOLUTE GROWTH
  • EXHIBIT 46 GLOBAL REGULATORY AFFAIRS OUTSOURCING SMALL & MID-SIZED COMPANIES MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 47 GLOBAL REGULATORY AFFAIRS OUTSOURCING SMALL & MID-SIZED COMPANIES MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 48 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 49 GLOBAL REGULATORY AFFAIRS OUTSOURCING LARGE-SIZED COMPANIES MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 50 GLOBAL REGULATORY AFFAIRS OUTSOURCING LARGE-SIZED COMPANIES MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 51 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 52 INCREMENTAL GROWTH BY END-USER 2021 & 2027
  • EXHIBIT 53 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY END-USER
  • EXHIBIT 54 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY END-USER: INCREMENTAL GROWTH
  • EXHIBIT 55 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY END-USER: ABSOLUTE GROWTH
  • EXHIBIT 56 GLOBAL REGULATORY AFFAIRS OUTSOURCING PHARMA & BIOTECH COMPANIES MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 57 GLOBAL REGULATORY AFFAIRS OUTSOURCING PHARMA & BIOTECH COMPANIES MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 58 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 59 GLOBAL REGULATORY AFFAIRS OUTSOURCING MEDICAL DEVICE COMPANIES MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 60 GLOBAL REGULATORY AFFAIRS OUTSOURCING MEDICAL DEVICE COMPANIES MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 61 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 62 GLOBAL REGULATORY AFFAIRS OUTSOURCING OTHER COMPANIES MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 63 GLOBAL REGULATORY AFFAIRS OUTSOURCING OTHER COMPANIES MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 64 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 65 INCREMENTAL GROWTH BY SERVICE TYPE 2021 & 2027
  • EXHIBIT 66 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY SERVICE TYPE
  • EXHIBIT 67 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY SERVICE TYPE: INCREMENTAL GROWTH
  • EXHIBIT 68 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY SERVICE TYPE: ABSOLUTE GROWTH
  • EXHIBIT 69 GLOBAL REGULATORY AFFAIRS OUTSOURCING PRE-AUTHORIZATION MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 70 GLOBAL REGULATORY AFFAIRS OUTSOURCING PRE-AUTHORIZATION MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 71 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 72 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKETING AUTHORIZATION MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 73 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKETING AUTHORIZATION MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 74 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 75 PRODUCT LIFECYCLE MANAGEMENT SERVICE
  • EXHIBIT 76 GLOBAL REGULATORY AFFAIRS OUTSOURCING POST-AUTHORIZATION MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 77 GLOBAL REGULATORY AFFAIRS OUTSOURCING POST-AUTHORIZATION MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 78 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 79 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 80 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY GEOGRAPHY
  • EXHIBIT 81 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY GEOGRAPHY: KEY COUNTRIES ($ MILLION)
  • EXHIBIT 82 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY GEOGRAPHY: INCREMENTAL GROWTH
  • EXHIBIT 83 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY GEOGRAPHY: ABSOLUTE GROWTH
  • EXHIBIT 84 NORTH AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET: KEY COUNTRIES
  • EXHIBIT 85 NORTH AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 86 REGULATORY AFFAIRS OUTSOURCING MARKET IN NORTH AMERICA 2021-2027 ($ MILLION)
  • EXHIBIT 87 INCREMENTAL GROWTH BY PRODUCT 2021 & 2027
  • EXHIBIT 88 INCREMENTAL GROWTH BY COMPANY SIZE 2021 & 2027
  • EXHIBIT 89 INCREMENTAL GROWTH BY END-USER 2021 & 2027
  • EXHIBIT 90 INCREMENTAL GROWTH BY SERVICE TYPE 2021 & 2027
  • EXHIBIT 91 INCREMENTAL GROWTH IN NORTH AMERICA 2021 & 2027
  • EXHIBIT 92 ELDERLY POPULATION AGED OVER 65 YEARS IN THE US ($ MILLION)
  • EXHIBIT 93 NUMBER OF APPROVED AND LAUNCHED BIOSIMILARS IN THE US
  • EXHIBIT 94 US FDA'S BIOSIMILAR DEVELOPMENT PROGRAMS
  • EXHIBIT 95 REGULATORY AFFAIRS OUTSOURCING MARKET IN THE US 2021-2027 ($ MILLION)
  • EXHIBIT 96 REGULATORY AFFAIRS OUTSOURCING MARKET IN CANADA 2021-2027 ($ MILLION)
  • EXHIBIT 97 EUROPE REGULATORY AFFAIRS OUTSOURCING MARKET: KEY COUNTRIES
  • EXHIBIT 98 BIOLOGICS AND NON-BIOLOGICS DEVELOPMENT IN EUROPE
  • EXHIBIT 99 EUROPE REGULATORY AFFAIRS OUTSOURCING MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 100 REGULATORY AFFAIRS OUTSOURCING MARKET IN EUROPE 2021-2027 ($ MILLION)
  • EXHIBIT 101 INCREMENTAL GROWTH BY PRODUCT 2021 & 2027
  • EXHIBIT 102 INCREMENTAL GROWTH BY COMPANY SIZE 2021 & 2027
  • EXHIBIT 103 INCREMENTAL GROWTH BY END-USER 2021 & 2027
  • EXHIBIT 104 INCREMENTAL GROWTH BY SERVICE TYPE 2021 & 2027
  • EXHIBIT 105 INCREMENTAL GROWTH IN EUROPE 2021 & 2027
  • EXHIBIT 106 AGING POPULATION IN GERMANY (MILLION)
  • EXHIBIT 107 REGULATORY AFFAIRS OUTSOURCING MARKET IN GERMANY 2021-2027 ($ MILLION)
  • EXHIBIT 108 REGULATORY AFFAIRS OUTSOURCING MARKET IN FRANCE 2021-2027 ($ MILLION)
  • EXHIBIT 109 REGULATORY AFFAIRS OUTSOURCING MARKET IN THE UK 2021-2027 ($ MILLION)
  • EXHIBIT 110 REGULATORY AFFAIRS OUTSOURCING MARKET IN ITALY 2021-2027 ($ MILLION)
  • EXHIBIT 111 MARKETING AUTHORIZATION PATHWAY IN SPAIN
  • EXHIBIT 112 REGULATORY AFFAIRS OUTSOURCING MARKET IN SPAIN 2021-2027 ($ MILLION)
  • EXHIBIT 113 APAC REGULATORY AFFAIRS OUTSOURCING MARKET: KEY COUNTRIES
  • EXHIBIT 114 APAC REGULATORY AFFAIRS OUTSOURCING MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 115 REGULATORY AFFAIRS OUTSOURCING MARKET IN APAC 2021-2027 ($ MILLION)
  • EXHIBIT 116 INCREMENTAL GROWTH BY PRODUCT 2021 & 2027
  • EXHIBIT 117 INCREMENTAL GROWTH BY COMPANY SIZE 2021 & 2027
  • EXHIBIT 118 INCREMENTAL GROWTH BY END-USER 2021 & 2027
  • EXHIBIT 119 INCREMENTAL GROWTH BY SERVICE TYPE 2021 & 2027
  • EXHIBIT 120 INCREMENTAL GROWTH IN APAC 2021 & 2027
  • EXHIBIT 121 PMDA'S SAFETY TRIANGLE
  • EXHIBIT 122 REGULATORY AFFAIRS OUTSOURCING MARKET IN JAPAN 2021-2027 ($ MILLION)
  • EXHIBIT 123 REGULATORY AFFAIRS OUTSOURCING MARKET IN CHINA 2021-2027 ($ MILLION)
  • EXHIBIT 124 SOUTH KOREA'S TOP CAUSES OF DEATHS PER 100,000 PEOPLE IN 2020
  • EXHIBIT 125 REGULATORY AFFAIRS OUTSOURCING MARKET IN SOUTH KOREA 2021-2027 ($ MILLION)
  • EXHIBIT 126 REGULATORY AFFAIRS OUTSOURCING MARKET IN INDIA 2021-2027 ($ MILLION)
  • EXHIBIT 127 PER CAPITA HEALTHCARE EXPENDITURE IN AUSTRALIA ($)
  • EXHIBIT 128 REGULATORY AFFAIRS OUTSOURCING MARKET IN AUSTRALIA 2021-2027 ($ MILLION)
  • EXHIBIT 129 LATIN AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET: KEY COUNTRIES
  • EXHIBIT 130 LATIN AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 131 DRUG PRODUCT REGULATORY HEALTH AUTHORITIES
  • EXHIBIT 132 REGULATORY AFFAIRS OUTSOURCING MARKET IN LATIN AMERICA 2021-2027 ($ MILLION)
  • EXHIBIT 133 INCREMENTAL GROWTH BY PRODUCT 2021 & 2027
  • EXHIBIT 134 INCREMENTAL GROWTH BY COMPANY SIZE 2021 & 2027
  • EXHIBIT 135 INCREMENTAL GROWTH BY END-USER 2021 & 2027
  • EXHIBIT 136 INCREMENTAL GROWTH BY SERVICE TYPE 2021 & 2027
  • EXHIBIT 137 INCREMENTAL GROWTH IN LATIN AMERICA 2021 & 2027
  • EXHIBIT 138 POPULATION AGED 65 AND ABOVE IN BRAZIL (MILLION)
  • EXHIBIT 139 REGULATORY AFFAIRS OUTSOURCING MARKET IN BRAZIL 2021-2027 ($ MILLION)
  • EXHIBIT 140 REGULATORY AFFAIRS OUTSOURCING MARKET IN MEXICO 2021-2027 ($ MILLION)
  • EXHIBIT 141 POPULATION AGED 65 AND ABOVE IN ARGENTINA (% OF TOTAL POPULATION)
  • EXHIBIT 142 REGULATORY AFFAIRS OUTSOURCING MARKET IN ARGENTINA 2021-2027 ($ MILLION)
  • EXHIBIT 143 MIDDLE EAST & AFRICA REGULATORY AFFAIRS OUTSOURCING MARKET: KEY COUNTRIES 2021
  • EXHIBIT 144 MIDDLE EAST & AFRICA REGULATORY AFFAIRS OUTSOURCING MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 145 CHALLENGES WITH FUNCTIONAL FOOD REGULATION IN THE MIDDLE EAST & AFRICA
  • EXHIBIT 146 REGULATORY AFFAIRS OUTSOURCING MARKET IN THE MIDDLE EAST & AFRICA 2021-2027 ($ MILLION)
  • EXHIBIT 147 INCREMENTAL GROWTH BY PRODUCT 2021 & 2027
  • EXHIBIT 148 INCREMENTAL GROWTH BY COMPANY SIZE 2021 & 2027
  • EXHIBIT 149 INCREMENTAL GROWTH BY END-USER 2021 & 2027
  • EXHIBIT 150 INCREMENTAL GROWTH BY SERVICE TYPE 2021 & 2027
  • EXHIBIT 151 INCREMENTAL GROWTH IN THE MIDDLE EAST & AFRICA 2021 & 2027
  • EXHIBIT 152 POPULATION AGED 65 YEARS AND ABOVE IN TURKEY (% OF TOTAL POPULATION)
  • EXHIBIT 153 REGULATORY AFFAIRS OUTSOURCING MARKET IN TURKEY 2021-2027 ($ MILLION)
  • EXHIBIT 154 REGULATORY AFFAIRS OUTSOURCING MARKET IN SAUDI ARABIA 2021-2027 ($ MILLION)
  • EXHIBIT 155 POPULATION AGED 60 AND ABOVE IN SOUTH AFRICA (% TOTAL POPULATION)
  • EXHIBIT 156 REGULATORY AFFAIRS OUTSOURCING MARKET IN SOUTH AFRICA 2021-2027 ($ MILLION)
  • EXHIBIT 157 REGULATORY AFFAIRS OUTSOURCING MARKET IN THE UAE 2021-2027 ($ MILLION)
  • EXHIBIT 158 GENPACT: TOTAL REVENUE 2018-2020 ($ MILLION)
  • EXHIBIT 159 GENPACT: REVENUE SHARE BY BUSINESS SEGMENTS 2020 (%)
  • EXHIBIT 160 GENPACT: REVENUE SHARE BY GEOGRAPHY 2020 (%)
  • EXHIBIT 161 LABCORP DRUG DEVELOPMENT: TOTAL REVENUE 2018-2020 ($ MILLION)
  • EXHIBIT 162 LABCORP DRUG DEVELOPMENT: REVENUE BY BUSINESS SEGMENTS 2020 (%)
  • EXHIBIT 163 LABCORP DRUG DEVELOPMENT: REVENUE BY GEOGRAPHY 2020 (%)
  • EXHIBIT 164 ICON: TOTAL REVENUE 2018-2020 ($ MILLION)
  • EXHIBIT 165 ICON: REVENUE BY GEOGRAPHY 2020 (%)
  • EXHIBIT 166 IQVIA: TOTAL REVENUE 2018-2020 ($ MILLION)
  • EXHIBIT 167 IQVIA: REVENUE SHARE BY GEOGRAPHY 2020 (%)
  • EXHIBIT 168 IQVIA: REVENUE BY BUSINESS SEGMENTS 2020 (%)
  • EXHIBIT 169 MEDPACE: TOTAL REVENUE 2018-2020 ($ MILLION)
  • EXHIBIT 170 MEDPACE: REVENUE SHARE BY CATEGORY 2020 (%)

LIST OF TABLES

  • TABLE 1 KEY CAVEATS
  • TABLE 2 CURRENCY CONVERSION 2015-2021
  • TABLE 3 MAJOR REGULATORY AUTHORITY IN DIFFERENT COUNTRIES
  • TABLE 4 LIST OF MAJOR BIOLOGICS & BIOSIMILARS
  • TABLE 5 TOP 10 PHARMA & BIOTECH COMPANIES BY REVENUE 2020
  • TABLE 6 NORTH AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET BY PRODUCT 2021-2027 ($ MILLION)
  • TABLE 7 NORTH AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET BY PRODUCT 2021-2027 (%)
  • TABLE 8 NORTH AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET BY COMPANY SIZE 2021-2027 ($ MILLION)
  • TABLE 9 NORTH AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET BY COMPANY SIZE 2021-2027 (%)
  • TABLE 10 NORTH AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET BY END-USER 2021-2027 ($ MILLION)
  • TABLE 11 NORTH AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET BY END-USER 2021-2027 (%)
  • TABLE 12 NORTH AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET BY SERVICE TYPE 2021-2027 ($ MILLION)
  • TABLE 13 NORTH AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET BY SERVICE TYPE 2021-2027 (%)
  • TABLE 14 EUROPE REGULATORY AFFAIRS OUTSOURCING MARKET BY PRODUCT 2021-2027 ($ MILLION)
  • TABLE 15 EUROPE REGULATORY AFFAIRS OUTSOURCING MARKET BY PRODUCT 2021-2027 (%)
  • TABLE 16 EUROPE REGULATORY AFFAIRS OUTSOURCING MARKET BY COMPANY SIZE 2021-2027 ($ MILLION)
  • TABLE 17 EUROPE REGULATORY AFFAIRS OUTSOURCING MARKET BY COMPANY SIZE 2021-2027 (%)
  • TABLE 18 EUROPE REGULATORY AFFAIRS OUTSOURCING MARKET BY END-USER 2021-2027 ($ MILLION)
  • TABLE 19 EUROPE REGULATORY AFFAIRS OUTSOURCING MARKET BY END-USER 2021-2027 (%)
  • TABLE 20 EUROPE REGULATORY AFFAIRS OUTSOURCING MARKET BY SERVICE TYPE 2021-2027 ($ MILLION)
  • TABLE 21 EUROPE REGULATORY AFFAIRS OUTSOURCING MARKET BY SERVICE TYPE 2021-2027 (%)
  • TABLE 22 APAC REGULATORY AFFAIRS OUTSOURCING MARKET BY PRODUCT 2021-2027 ($ MILLION)
  • TABLE 23 APAC REGULATORY AFFAIRS OUTSOURCING MARKET BY PRODUCT 2021-2027 (%)
  • TABLE 24 APAC REGULATORY AFFAIRS OUTSOURCING MARKET BY COMPANY SIZE 2021-2027 ($ MILLION)
  • TABLE 25 APAC REGULATORY AFFAIRS OUTSOURCING MARKET BY COMPANY SIZE 2021-2027 (%)
  • TABLE 26 APAC REGULATORY AFFAIRS OUTSOURCING MARKET BY END-USER 2021-2027 ($ MILLION)
  • TABLE 27 APAC REGULATORY AFFAIRS OUTSOURCING MARKET BY END-USER 2021-2027 (%)
  • TABLE 28 APAC REGULATORY AFFAIRS OUTSOURCING MARKET BY SERVICE TYPE 2021-2027 ($ MILLION)
  • TABLE 29 APAC REGULATORY AFFAIRS OUTSOURCING MARKET BY SERVICE TYPE 2021-2027 (%)
  • TABLE 30 LATIN AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET BY PRODUCT 2021-2027 ($ MILLION)
  • TABLE 31 LATIN AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET BY PRODUCT 2021-2027 (%)
  • TABLE 32 LATIN AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET BY COMPANY SIZE 2021-2027 ($ MILLION)
  • TABLE 33 LATIN AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET BY COMPANY SIZE 2021-2027 (%)
  • TABLE 34 LATIN AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET BY END-USER 2021-2027 ($ MILLION)
  • TABLE 35 LATIN AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET BY END-USER 2021-2027 (%)
  • TABLE 36 LATIN AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET BY SERVICE TYPE 2021-2027 ($ MILLION)
  • TABLE 37 LATIN AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET BY SERVICE TYPE 2021-2027 (%)
  • TABLE 38 MIDDLE EAST & AFRICA REGULATORY AFFAIRS OUTSOURCING MARKET BY PRODUCT 2021-2027 ($ MILLION)
  • TABLE 39 MIDDLE EAST & AFRICA REGULATORY AFFAIRS OUTSOURCING MARKET BY PRODUCT 2021-2027 (%)
  • TABLE 40 MIDDLE EAST & AFRICA REGULATORY AFFAIRS OUTSOURCING MARKET BY COMPANY SIZE 2021-2027 ($ MILLION)
  • TABLE 41 MIDDLE EAST & AFRICA REGULATORY AFFAIRS OUTSOURCING MARKET BY COMPANY SIZE 2021-2027 (%)
  • TABLE 42 MIDDLE EAST & AFRICA REGULATORY AFFAIRS OUTSOURCING MARKET BY END-USER 2021-2027 ($ MILLION)
  • TABLE 43 MIDDLE EAST & AFRICA REGULATORY AFFAIRS OUTSOURCING MARKET BY END-USER 2021-2027 (%)
  • TABLE 44 MIDDLE EAST & AFRICA REGULATORY AFFAIRS OUTSOURCING MARKET BY SERVICE TYPE 2021-2027 ($ MILLION)
  • TABLE 45 MIDDLE EAST & AFRICA REGULATORY AFFAIRS OUTSOURCING MARKET BY SERVICE TYPE 2021-2027 (%)
  • TABLE 46 GENPACT: MAJOR SERVICE OFFERINGS
  • TABLE 47 LABCORP DRUG DEVELOPMENT: MAJOR SERVICE OFFERINGS
  • TABLE 48 FREYR: MAJOR SERVICE OFFERINGS
  • TABLE 49 ICON: MAJOR SERVICE OFFERINGS
  • TABLE 50 IQVIA: MAJOR SERVICE OFFERINGS
  • TABLE 51 MEDPACE: MAJOR PRODUCT OFFERINGS
  • TABLE 52 PAREXEL INTERNATIONAL: MAJOR PRODUCT OFFERINGS
  • TABLE 53 PPD: MAJOR PRODUCT OFFERINGS
  • TABLE 54 ACCENTURE: MAJOR SERVICE OFFERINGS
  • TABLE 55 BLUEREG: MAJOR SERVICE OFFERINGS
  • TABLE 56 INTERTEK GROUP: MAJOR SERVICE OFFERINGS
  • TABLE 57 LACHMAN CONSULTANTS: MAJOR SERVICE OFFERINGS
  • TABLE 58 NDA GROUP: MAJOR SERVICE OFFERINGS
  • TABLE 59 PROPHARMA GROUP: MAJOR SERVICE OFFERINGS
  • TABLE 60 PHARMALEX: MAJOR SERVICE OFFERINGS
  • TABLE 61 PHARMEXON: MAJOR SERVICE OFFERINGS
  • TABLE 62 PROMEDICA INTERNATIONAL: MAJOR SERVICE OFFERINGS
  • TABLE 63 CRITERIUM: MAJOR SERVICE OFFERINGS
  • TABLE 64 DICENTRA: MAJOR SERVICE OFFERINGS
  • TABLE 65 NUVENTRA PHARMA SCIENCES: MAJOR SERVICE OFFERINGS
  • TABLE 66 PHARMALEAF: MAJOR SERVICE OFFERINGS
  • TABLE 67 MAVEN REGULATORY SOLUTIONS: MAJOR SERVICE OFFERINGS
  • TABLE 68 GLOBAL REGULATORY PARTNERS: MAJOR SERVICE OFFERINGS
  • TABLE 69 SOFPROMED: MAJOR SERVICE OFFERINGS
  • TABLE 70 CHARLES RIVER LABORATORIES: MAJOR SERVICE OFFERINGS
  • TABLE 71 CAMBRIDGE REGULATORY SERVICES: MAJOR SERVICE OFFERINGS
  • TABLE 72 APC GROUP: MAJOR SERVICE OFFERINGS
  • TABLE 73 REAL REGULATORY: MAJOR SERVICE OFFERINGS
  • TABLE 74 VOISIN CONSULTING LIFE SCIENCES (VCLS): MAJOR SERVICE OFFERINGS
  • TABLE 75 REGULATORY PHARMA NET: MAJOR SERVICE OFFERINGS
  • TABLE 76 BIOMAPAS: MAJOR SERVICE OFFERINGS
  • TABLE 77 REGENOLD: MAJOR SERVICE OFFERINGS
  • TABLE 78 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY PRODUCT 2021-2027 ($ MILLION)
  • TABLE 79 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY PRODUCT 2021-2027 (%)
  • TABLE 80 NORTH AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET BY PRODUCT 2021-2027 ($ MILLION)
  • TABLE 81 NORTH AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET BY PRODUCT 2021-2027 (%)
  • TABLE 82 EUROPE REGULATORY AFFAIRS OUTSOURCING MARKET BY PRODUCT 2021-2027 ($ MILLION)
  • TABLE 83 EUROPE REGULATORY AFFAIRS OUTSOURCING MARKET BY PRODUCT 2021-2027 (%)
  • TABLE 84 APAC REGULATORY AFFAIRS OUTSOURCING MARKET BY PRODUCT 2021-2027 ($ MILLION)
  • TABLE 85 APAC REGULATORY AFFAIRS OUTSOURCING MARKET BY PRODUCT 2021-2027 (%)
  • TABLE 86 LATIN AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET BY PRODUCT 2021-2027 ($ MILLION)
  • TABLE 87 LATIN AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET BY PRODUCT 2021-2027 (%)
  • TABLE 88 MIDDLE EAST & AFRICA REGULATORY AFFAIRS OUTSOURCING MARKET BY PRODUCT 2021-2027 ($ MILLION)
  • TABLE 89 MIDDLE EAST & AFRICA REGULATORY AFFAIRS OUTSOURCING MARKET BY PRODUCT 2021-2027 (%)
  • TABLE 90 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY COMPANY SIZE 2021-2027 ($ MILLION)
  • TABLE 91 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY COMPANY SIZE 2021-2027 (%)
  • TABLE 92 NORTH AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET BY COMPANY SIZE 2021-2027 ($ MILLION)
  • TABLE 93 NORTH AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET BY COMPANY SIZE 2021-2027 (%)
  • TABLE 94 EUROPE REGULATORY AFFAIRS OUTSOURCING MARKET BY COMPANY SIZE 2021-2027 ($ MILLION)
  • TABLE 95 EUROPE REGULATORY AFFAIRS OUTSOURCING MARKET BY COMPANY SIZE 2021-2027 (%)
  • TABLE 96 APAC REGULATORY AFFAIRS OUTSOURCING MARKET BY COMPANY SIZE 2021-2027 ($ MILLION)
  • TABLE 97 APAC REGULATORY AFFAIRS OUTSOURCING MARKET BY COMPANY SIZE 2021-2027 (%)
  • TABLE 98 LATIN AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET BY COMPANY SIZE 2021-2027 ($ MILLION)
  • TABLE 99 LATIN AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET BY COMPANY SIZE 2021-2027 (%)
  • TABLE 100 MIDDLE EAST & AFRICA REGULATORY AFFAIRS OUTSOURCING MARKET BY COMPANY SIZE 2021-2027 ($ MILLION)
  • TABLE 101 MIDDLE EAST & AFRICA REGULATORY AFFAIRS OUTSOURCING MARKET BY COMPANY SIZE 2021-2027 (%)
  • TABLE 102 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY END-USER 2021-2027 ($ MILLION)
  • TABLE 103 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY END-USER 2021-2027 (%)
  • TABLE 104 REGULATORY AFFAIRS OUTSOURCING MARKET BY END-USER 2021-2027 ($ MILLION)
  • TABLE 105 REGULATORY AFFAIRS OUTSOURCING MARKET BY END-USER 2021-2027 (%)
  • TABLE 106 EUROPE REGULATORY AFFAIRS OUTSOURCING MARKET BY END-USER 2021-2027 ($ MILLION)
  • TABLE 107 EUROPE REGULATORY AFFAIRS OUTSOURCING MARKET BY END-USER 2021-2027 (%)
  • TABLE 108 APAC REGULATORY AFFAIRS OUTSOURCING MARKET BY END-USER 2021-2027 ($ MILLION)
  • TABLE 109 APAC REGULATORY AFFAIRS OUTSOURCING MARKET BY END-USER 2021-2027 (%)
  • TABLE 110 LATIN AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET BY END-USER 2021-2027 ($ MILLION)
  • TABLE 111 LATIN AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET BY END-USER 2021-2027 (%)
  • TABLE 112 MIDDLE EAST & AFRICA REGULATORY AFFAIRS OUTSOURCING MARKET BY END-USER 2021-2027 ($ MILLION)
  • TABLE 113 MIDDLE EAST & AFRICA REGULATORY AFFAIRS OUTSOURCING MARKET BY END-USER 2021-2027 (%)
  • TABLE 114 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY SERVICE TYPE 2021-2027 ($ MILLION)
  • TABLE 115 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY SERVICE TYPE 2021-2027 (%)
  • TABLE 116 REGULATORY AFFAIRS OUTSOURCING MARKET BY SERVICE TYPE 2021-2027 ($ MILLION)
  • TABLE 117 REGULATORY AFFAIRS OUTSOURCING MARKET BY SERVICE TYPE 2021-2027 (%)
  • TABLE 118 EUROPE REGULATORY AFFAIRS OUTSOURCING MARKET BY SERVICE TYPE 2021-2027 ($ MILLION)
  • TABLE 119 EUROPE REGULATORY AFFAIRS OUTSOURCING MARKET BY SERVICE TYPE 2021-2027 (%)
  • TABLE 120 APAC REGULATORY AFFAIRS OUTSOURCING MARKET BY SERVICE TYPE 2021-2027 ($ MILLION)
  • TABLE 121 APAC REGULATORY AFFAIRS OUTSOURCING MARKET BY SERVICE TYPE 2021-2027 (%)
  • TABLE 122 LATIN AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET BY SERVICE TYPE 2021-2027 ($ MILLION)
  • TABLE 123 LATIN AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET BY SERVICE TYPE 2021-2027 (%)
  • TABLE 124 MIDDLE EAST & AFRICA REGULATORY AFFAIRS OUTSOURCING MARKET BY SERVICE TYPE 2021-2027 ($ MILLION)
  • TABLE 125 MIDDLE EAST & AFRICA REGULATORY AFFAIRS OUTSOURCING MARKET BY SERVICE TYPE 2021-2027 (%)
  • TABLE 126 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 127 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 128 GLOBAL REGULATORY AFFAIRS OUTSOURCING DRUGS MARKET 2021-2027 ($ MILLION)
  • TABLE 129 GLOBAL REGULATORY AFFAIRS OUTSOURCING DRUGS MARKET 2021-2027 (%)
  • TABLE 130 GLOBAL REGULATORY AFFAIRS OUTSOURCING BIOLOGICS MARKET 2021-2027 ($ MILLION)
  • TABLE 131 GLOBAL REGULATORY AFFAIRS OUTSOURCING BIOLOGICS MARKET 2021-2027 (%)
  • TABLE 132 GLOBAL REGULATORY AFFAIRS OUTSOURCING MEDICAL DEVICES MARKET 2021-2027 ($ MILLION)
  • TABLE 133 GLOBAL REGULATORY AFFAIRS OUTSOURCING MEDICAL DEVICES MARKET 2021-2027 (%)
  • TABLE 134 GLOBAL REGULATORY AFFAIRS OUTSOURCING OTHER PRODUCTS MARKET 2021-2027 ($ MILLION)
  • TABLE 135 GLOBAL REGULATORY AFFAIRS OUTSOURCING OTHER PRODUCTS MARKET 2021-2027 (%)
  • TABLE 136 GLOBAL REGULATORY AFFAIRS OUTSOURCING SMALL & MID-SIZED COMPANIES MARKET 2021-2027 ($ MILLION)
  • TABLE 137 GLOBAL REGULATORY AFFAIRS OUTSOURCING SMALL & MID-SIZED COMPANIES MARKET 2021-2027 (%)
  • TABLE 138 GLOBAL REGULATORY AFFAIRS OUTSOURCING LARGE-SIZED COMPANIES MARKET 2021-2027 ($ MILLION)
  • TABLE 139 GLOBAL REGULATORY AFFAIRS OUTSOURCING LARGE-SIZED COMPANIES MARKET 2021-2027 (%)
  • TABLE 140 GLOBAL REGULATORY AFFAIRS OUTSOURCING PHARMA & BIOTECH COMPANIES MARKET 2021-2027 ($ MILLION)
  • TABLE 141 GLOBAL REGULATORY AFFAIRS OUTSOURCING PHARMA & BIOTECH COMPANIES MARKET 2021-2027 (%)
  • TABLE 142 GLOBAL REGULATORY AFFAIRS OUTSOURCING MEDICAL DEVICE COMPANIES MARKET 2021-2027 ($ MILLION)
  • TABLE 143 GLOBAL REGULATORY AFFAIRS OUTSOURCING MEDICAL DEVICE COMPANIES MARKET 2021-2027 (%)
  • TABLE 144 GLOBAL REGULATORY AFFAIRS OUTSOURCING OTHER COMPANIES MARKET 2021-2027 ($ MILLION)
  • TABLE 145 GLOBAL REGULATORY AFFAIRS OUTSOURCING OTHER COMPANIES MARKET 2021-2027 (%)
  • TABLE 146 GLOBAL REGULATORY AFFAIRS OUTSOURCING PRE-AUTHORIZATION MARKET 2021-2027 ($ MILLION)
  • TABLE 147 GLOBAL REGULATORY AFFAIRS OUTSOURCING PRE-AUTHORIZATION MARKET 2021-2027 (%)
  • TABLE 148 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKETING AUTHORIZATION MARKET 2021-2027 ($ MILLION)
  • TABLE 149 GLOBAL REGULATORY AFFAIRS OUTSOURCING MARKETING AUTHORIZATION MARKET 2021-2027 (%)
  • TABLE 150 GLOBAL REGULATORY AFFAIRS OUTSOURCING POST-AUTHORIZATION MARKET 2021-2027 ($ MILLION)
  • TABLE 151 GLOBAL REGULATORY AFFAIRS OUTSOURCING POST-AUTHORIZATION MARKET 2021-2027 (%)